Payment overview · 2025
General Payments
$85.68
3 reported records · 2 companies
Healthcare provider profile · identity verified
Eric Scott Mcclanahan, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BLUEFIELD, WV · NPI 1619162237
Verified facts
What the public records show
CMS Open Payments records show Eric Scott Mcclanahan, D.O. received $85.68 in general payments during 2025 across 3 reported records.
Averitas Pharma Inc. accounted for 79.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $68.01 | 79.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.67 | 20.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.68 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $68.01 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 532 | 153 |
| Omeprazole | Omeprazole | 368 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 82 |
| Montelukast Sodium | Montelukast Sodium | 287 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 281 | 38 |
| Furosemide | Furosemide | 260 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 62 |
| Lisinopril | Lisinopril | 251 | 76 |
| Famotidine | Famotidine | 250 | 73 |
| Metformin Hcl | Metformin Hcl | 231 | 64 |
| Losartan Potassium | Losartan Potassium | 208 | 64 |
| Allopurinol | Allopurinol | 198 | 46 |
| Potassium Chloride | Potassium Chloride | 197 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 55 |
| Gabapentin | Gabapentin | 178 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 38 |
| Tramadol Hcl | Tramadol Hcl | 140 | 25 |
| Trazodone Hcl | Trazodone Hcl | 137 | 44 |
| Ozempic | Semaglutide | 132 | 17 |
| Carvedilol | Carvedilol | 107 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 28 |
| Ibuprofen | Ibuprofen | 99 | 38 |
| Simvastatin | Simvastatin | 99 | 29 |
| Sertraline Hcl | Sertraline Hcl | 97 | 27 |
| Prednisone | Prednisone | 93 | 40 |
| Jardiance | Empagliflozin | 91 | 27 |
| Ezetimibe | Ezetimibe | 88 | 28 |
| Glimepiride | Glimepiride | 88 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 17 |
| Eliquis | Apixaban | 78 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Baclofen | Baclofen | 72 | 22 |
| Glipizide | Glipizide | 69 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 20 |
| Ondansetron Odt | Ondansetron | 64 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 14 |
| Meloxicam | Meloxicam | 61 | 18 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 60 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 17 |
| Alendronate Sodium | Alendronate Sodium | 55 | 14 |
| Januvia | Sitagliptin Phosphate | 55 | 20 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Farxiga | Dapagliflozin Propanediol | 51 | 18 |
| Fenofibrate | Fenofibrate | 51 | suppressed |
| Lorazepam | Lorazepam | 51 | 14 |
| Finasteride | Finasteride | 50 | 14 |
| Klor-Con M20 | Potassium Chloride | 50 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 14 |
| Celecoxib | Celecoxib | 47 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 12 |
| Trulicity | Dulaglutide | 43 | 11 |
| Atenolol | Atenolol | 42 | 14 |
| Methylprednisolone | Methylprednisolone | 42 | 38 |
| Nystatin | Nystatin | 42 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 15 |
| Linzess | Linaclotide | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 27 |
| Spironolactone | Spironolactone | 38 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 11 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 29 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Fentanyl | Fentanyl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 14 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 25 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Torsemide | Torsemide | 30 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 11 |
| Cilostazol | Cilostazol | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Cholestyramine Light | Cholestyramine | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.68 · 3 records | Averitas Pharma Inc. | QUTENZA, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error